Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

• ClinicalTrials.gov Identifier: NCT00958074
• Recruitment Status: Terminated
• First Posted: August 13, 2009
• Results First Posted: December 15, 2014
• Last Update Posted: October 18, 2018
• Sponsor: University of Washington
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Andrei Shustov, University of Washington

Study Description

Brief Summary:

This phase II trial studies the side effects and how well vorinostat works in treating patients with primary cutaneous T-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

Condition or disease	Intervention/treatment	Phase
Cutaneous T-cell Lymphoma Stage I; Cutaneous T-cell Lymphoma Stage II; Cutaneous T-cell Lymphoma Stage III; Cutaneous T-cell Lymphoma Stage IV	Drug: vorinostat; Other: flow cytometry; Other: laboratory biomarker analysis	Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the objective response rate to treatment with dose-adjusted Vorinostat schedule in subjects with cutaneous T-cell lymphoma (CTCL) who did not receive prior systematic therapy or have been treated with single agent targretin (bexarotene).

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of dose-adjusted Vorinostat schedule when administered to patients with primary cutaneous T-cell lymphoma who did not receive prior systematic therapy or have been treated with single agent targretin.

II. To determine the time to objective response in subjects with CTCL treated with dose-adjusted schedule of Vorinostat as primary therapy.

III To determine the duration of objective response in subjects with CTCL.

IV. To determine the time to loss of objective response.

V. To determine the objective response rate of extracutaneous manifestations of CTCL (lymph node enlargement, Sezary cells in peripheral blood).

VI. To compare the efficacy, toxicity and tolerability of dose-adjusted schedule to currently recommended flat dose of Vorinostat in subjects with CTCL.

OUTLINE: Patients are assigned to 1 of 2 treatment arms according to age (< 65 vs >= 65 years old).

COHORT I (>= 65 years old): Patients receive 200 mg vorinostat orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

COHORT II (< 65 years old): Patients receive 400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for at least 30 days.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 11 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Prospective Non-Randomized Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin
• Study Start Date: July 2009
• Actual Primary Completion Date: February 2013
• Actual Study Completion Date: November 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort I (>=65 years old); 200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.	Drug: vorinostat; Given PO; Other Names: L-001079038; SAHA; suberoylanilide hydroxamic acid; Zolinza; Other: flow cytometry; correlative study; Other: laboratory biomarker analysis; correlative study
Experimental: Cohort II (<65 years old); 400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.	Drug: vorinostat; Given PO; Other Names: L-001079038; SAHA; suberoylanilide hydroxamic acid; Zolinza; Other: flow cytometry; correlative study; Other: laboratory biomarker analysis; correlative study

Outcome Measures

Primary Outcome Measures :

1. Objective Response [ Time Frame: After at least 14 days. With Confirmation after additional 28 days. ]
   Defined as either no evidence of clinical disease or marked improvement (>= 50%) decrease in the modified Severity-Weighted Assessment Tool (mSWAT) skin assessment score compared to baseline.

Secondary Outcome Measures :

1. Objective Response Rate of Extracutaneous Manifestations of CTCL (Lymph Node Enlargement, Sezary Cells in Peripheral Blood); [ Time Frame: Up to 30 days post-treatment ]
   Assessed by changes in the sum of the products in the greatest diameters of enlarged lymph nodes by serial computed tomography (CT) or positron emission tomography (PET)/CT scans.
2. Occurrences of Dose Adjustment as Measured by Safety/Toxicity [ Time Frame: Up to 30 days post-treatment ]
   Toxicities will be graded in severity according to the guidelines outlined in the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.
3. Number of Participants With Overall Response as Measured by Sezary Cell Count [ Time Frame: Baseline to 30 days post-treatment ]
   Overall response defined by a clinically significant decrease in Sezary cell count (>50% decrease from baseline).
4. Changes in the Physicians Serial Assessment of Erythroderma Score [ Time Frame: Baseline to 30 days post-treatment ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Males or non-pregnant females
• Histologically confirmed diagnosis of CTCL, including mycosis fungoides and/or Sezary syndrome
• Documentation of diagnosis by histologic examination should be available
• Subjects with CTCL stages IB, IIA, IIB, III, or IVA who have not received any prior systemic therapies
• Anticipated life expectancy greater than 6 months
• Performance status 0, 1, or 2 by Eastern Cooperative Oncology Group (ECOG) criteria
• Written informed consent to participate in the study
• Absolute neutrophil count (ANC) >= 1,000/mcL
• Platelets >= 75,000/mcL
• Hemoglobin >= 9 g/dL
• Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) unless receiving therapeutic anticoagulation
• Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is receiving therapeutic anticoagulation
• Serum creatinine =< 1.5 X ULN OR calculated creatinine clearance >= 60 mL/min for patients with creatinine levels > 1.5 X institutional ULN; creatinine clearance should be calculated per institutional standard
• Serum total bilirubin =< 2 X ULN
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic aminotransaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic aminotransaminase [SGPT]) =< 3.0 X ULN
• Alkaline Phosphatase (liver fraction) =< 3.0 X ULN

Exclusion Criteria:

• Proven or suspected extracutaneous visceral CTCL involvement (M1) (CTCL stage IVB)
• Presence of lymphadenopathy is permitted
• ECOG performance status > 2
• Concomitant use of any anti-cancer therapy or immune modifier
• Concomitant use of any investigational agent or device
• Concomitant therapy with any other anti-CTCL therapy, or radiation therapy (topical corticosteroids or low dose oral corticosteroids [=< 10 mg/day prednisone or equivalent] will not be excluded, but if used, the dose and schedule must be stable during the two weeks immediately prior to study entry)
• Use of any previous systemic therapy (except single agent targretin), total skin electron beam (TSEB) therapy or extracorporeal photopheresis
• Evidence of clinically significant (uncontrolled) hypo- or hyperthyroidism
• Poorly controlled diabetes mellitus as evidenced by hemoglobin (Hgb)A1c > 6.5 mg/dl
• Recent (in the past 6 months) medically significant cardiac event (i.e. myocardial infarction, cardiac surgery)
• Presence of congestive heart failure (New York Heart Association [NYHA] class IV) or angina (NYHA class IV) or presence of a medically significant arrhythmia
• Congenital long QT syndrome
• Corrected QT interval > 480 msec on screening electrocardiogram (ECG)
• Presence of uncontrolled hypertension manifested by systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 100 mmHg
• Documented current active infection with human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C, and/or cytomegalovirus (CMV)
• Presence of uncontrolled bacterial or viral infection (subject may be receiving chronic antimicrobial therapy)
• History of culture-documented bacteremia in the previous 2 weeks
• Concurrent therapy with any histone deacetylase (HDAC)-like compound; patients treated with valproic acid for epilepsy may enroll after a 30 day washout period
• Recent change (in the past 2 weeks) in the doses or regimens of medication used for any chronic non-oncologic conditions for reasons of worsening of chronic illness (change in doses of chronic medications associated with improvement in a chronic illness are not exclusion criteria)
• Presence of any acute or chronic non-oncologic disease which, in the opinion of the investigator, is medically uncontrolled
• History of a prior malignancy with the exception of cervical intraepithelial neoplasia; non-melanoma skin cancer; adequately treated localized prostate carcinoma with prostate specific antigen (PSA) < 1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and/or who is deemed at low risk for recurrence (< 30% probability) by his/her treating physician
• Patient with a "currently active" second malignancy, other than nonmelanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled
• Any significant medical or psychiatric condition that, in the opinion of the investigator, might prevent the subject from complying with all required study procedures
• Women of childbearing potential must have a pregnancy test within 28 days prior to registration, and must use an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 3 months after the study
• Females of childbearing potential and sexually active males, if indicated, must be willing and able to use two methods of contraception that are adequate to prevent or minimize risk of pregnancy for the duration of the study; one of which must be a barrier method
• Patient has symptomatic ascites or pleural effusion (a patient who is clinically stable following treatment for these conditions is eligible)
• Patient has had allogeneic transplant
• Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs

Contacts and Locations

Locations

United States, Washington

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Seattle, Washington, United States, 98109

Sponsors and Collaborators

University of Washington

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Andrei Shustov; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

More Information

• Responsible Party: Andrei Shustov, Principal Investigator, University of Washington
• ClinicalTrials.gov Identifier: NCT00958074
• Other Study ID Numbers: 6914; NCI-2009-01231 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
• First Posted: August 13, 2009
• Results First Posted: December 15, 2014
• Last Update Posted: October 18, 2018
• Last Verified: September 2018

Additional relevant MeSH terms:

Lymphoma; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, Non-Hodgkin; Vorinostat; Antineoplastic Agents; Histone Deacetylase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action